Pence, Brian W.a; O’Donnell, Julie K.b; Gaynes, Bradley N.c
aDepartment of Community and Family Medicine, Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, Durham
bDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill
cDepartment of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Correspondence to Brian W. Pence, PhD, MPH, Associate Professor, Department of Community and Family Medicine, Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, 2812 Erwin Road, Box 90392, Durham, NC 27705, USA. Tel: +1 919 613 5443; e-mail: email@example.com
Received 10 November, 2011
Revised 3 January, 2012
Accepted 19 January, 2012
Depression is the most common mental health disorder among HIV patients, affecting 20–30% of those engaged in HIV medical care . In addition to being a serious, costly, and potentially fatal medical condition in its own right, depression poses challenging barriers to effective medical care at multiple points along the continuum of HIV medical care engagement and treatment , or what has become known as the ‘HIV treatment cascade’ .
The HIV treatment continuum shows that for an HIV-infected individual to achieve virologic suppression, the individual must be aware of his or her diagnosis, engage in HIV medical care, remain in care, start antiretroviral therapy (ART), and adhere to ART. Thus, high population-level success rates in testing, linking and retaining in care, initiating ART, and maximizing adherence are essential to maximally reduce ‘community viral load’ . However, with substantial attrition at each step along the HIV treatment continuum, a recent analysis estimated that only 19% of HIV-infected individuals in the USA currently have suppressed virus .
Attrition along the steps of the HIV-treatment continuum is related to many factors, but in particular is strongly predicted by depression. Mounting evidence suggests that effectively treating depression in HIV patients may have benefits for their HIV-treatment retention, ART adherence, and virologic suppression, and, therefore, for community viral load [5,6].
However, the response to depression in HIV patients suffers from its own ‘treatment cascade.’ Depression in HIV patients, although highly prevalent, is widely unrecognized . When clinically recognized, the condition often goes untreated . When treated, providers’ adherence to best-practices guidelines about dosing, duration, and monitoring of antidepressants is low, meaning that many patients fail to receive an adequate treatment course and, therefore, fail to benefit from treatment .
In the nationally representative HIV Cost and Service Utilization Survey, 45% of those meeting diagnostic criteria for a major depressive disorder (MDD) had documentation of a diagnosis of depression in their medical record .
In the multisite HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study of patients triply diagnosed with mental illness, substance use, and HIV, only 59% had received any mental health treatment in the past 3 months; of those with a mood disorder, 40% were taking a psychotropic medication . Other studies have reported similar results .
Adequate psychotherapeutic treatments generally require at least eight sessions . For antidepressants, a core principle involves regular evaluation of depressive symptom response and side effects, combined with increasing antidepressant doses if response has not been achieved . We did not identify any data on adequacy of depression treatment for HIV patients. The National Comorbidity Study Replication estimated that, in the US general population, 64% of those being treated in the specialty mental health sector and 41% of those being treated in the general medical sector were receiving adequate depression treatment, based on what is likely a generous definition of adequacy .
Standard psychotherapeutic and pharmacological treatments work as well or better in achieving full remission from depression in HIV patients compared to the general population. In controlled and open-label trials of antidepressants in HIV patients, remission rates have ranged from 17% to 100% with a median of 72% .
Based on these and other studies, we used the following estimates and 95% Bayesian credible intervals  to define the depression treatment cascade for HIV patients (Fig. 1) : 45% (40–50%) of MDD cases in HIV patients are recognized clinically; of those recognized clinically, 40% (30–50%) are being treated; of those treated, 40% (25–55%) are being treated adequately; and of those receiving adequate treatment, 70% (55–85%) have achieved remission.
Combining these estimates suggests that of all HIV patients with MDD, 18% (14–24%) are receiving any treatment, 7% (4–12%) are receiving adequate treatment, and 5% (3–9%) have achieved remission. Thus, we estimate that 82% of HIV patients with depression are not receiving any treatment, 93% are not receiving adequate treatment, and 95% have not achieved remission.
Although effective medical treatments for depression are well established, the successful treatment of depression in HIV patients is a rare event due to shortcomings in clinical recognition, treatment initiation, and treatment adequacy. Substantial gains in depression remission rates are only likely by targeting multiple steps along this cascade; for example, by combining routine depression screening with collaborative care models that give HIV providers decision support in prescribing and adjusting antidepressants within the HIV ‘medical home’ . Mental healthcare models for HIV patients that address these gaps will be critical both to improve quality of life and to mitigate the impact of depression on community viral load.
All authors meet ICMJE criteria for authorship.
B.W.P. conceived the design. B.W.P. and J.K.O. wrote the first draft of the article. B.W.P., J.K.O., and B.N.G. reviewed the literature, wrote the article, and agree with the manuscript's results and conclusions.
Conflicts of interest
There are no conflicts of interest.
Role of funding source: BWP and BNG's contribution to this paper was supported by grant R01MH086362 of the National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. BWP had full access to all data and had final responsibility for the decision to publish.
Ethics approval: This manuscript did not involve research with human subjects and therefore did not receive ethics approval.
1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721–728.
2. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793–800.
3. Mugavero MJ. Guidelines for improving HIV treatment ‘adherence’: The big picture. 6th International Conference on HIV Treatment and Prevention Adherence. Miami, FL: 2011.
4. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
5. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:847–856.
6. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:384–390.
7. Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing?. J Gen Intern Med 2003; 18:450–460.
8. Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Ettner SL. Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. J Acquir Immune Defic Syndr 2008; 47:449–458.
9. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–3105.
10. Israelski DM, Prentiss DE, Lubega S, et al. Psychiatric co-morbidity in vulnerable populations receiving primary care for HIV/AIDS. AIDS Care 2007; 19:220–225.
11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. Washington, DC: American Psychiatric Association Press; 2010.
12. Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STD 2005; 19:813–822.
13. Carlin BP, Louis TA. Bayesian Methods for Data Analysis. 3rd ed.Boca Raton:Chapman and Hall/CRC Press; 2009.
© 2012 Lippincott Williams & Wilkins, Inc.